{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"12.920","floor":"11.700"},"ipodate":{"start":"2020-11-30 00:00:00","end":"2020-12-03 00:00:00"},"minimumcapital":"13050.20","subscribed":"78.54","marketcap":"95.06億","H_marketcap":"--","pe":"--","codesrate":"10.00","link":"https://staticpdf.iqdii.com/stockdata/notice/02142/2020/2020113000018_c.pdf","ipopricing":"12.380","resultdate":"2020-12-09 00:00:00","enddate":"2020-12-03 00:00:00","listeddate":"2020-12-10 00:00:00","issuenumber":"13822.10萬","issuenumberhK":"5529.00萬","issuenumberother":"8293.10萬","grayprice":"12.34","sponsors":"摩根士丹利亞洲有限公司,美林遠東有限公司,中信里昂證券資本市場有限公司","raisemoney":"159880.00萬","use":"1、約591.5百萬港元（占37%）預期將用于撥資我們的核心產品；\n2、約367.7百萬港元（占23%）預期將用于撥資我們的支柱資產HBM4003在大中華區及澳洲的進行中及計劃進行的臨床試驗、籌備在大中華區、美國及其他司法權區的注冊備案及潛在商業化推出；\n3、約239.8百萬港元（占15%）預期將用于撥資我們其他正在尋求IND批準及尚未開始臨床試驗或臨床前研究的候選藥物的研發；\n4、約191.9百萬港元（占12%）預期將用于撥資和鉑抗體平臺產生的創新型分子發現；\n5、約79.9百萬港元（占5%）預期將用于撥資持續改進平臺技術、利用和鉑抗體平臺尋求授權及合作機會；\n6、約127.9百萬港元（占8%）預期將用作營運資金及其他一般企業用途。","shares":1000,"leadagent":"摩根士丹利亞洲有限公司,美林遠東有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,美林遠東有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司,海通國際證券有限公司,中銀國際亞洲有限公司","coordinator":"摩根士丹利亞洲有限公司,美林遠東有限公司,中信里昂證券有限公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司","firstDayOpen":"11.94","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E02142","name":"和鉑醫藥－Ｂ","fullname":"和鉑醫藥控股有限公司"},"institutioninfo":{"principaloffice":"中國上海徐匯區楓林路420號楓林國際大廈二期A座12樓","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333","chairman":"王勁松","secretary":"呂穎一","telephone":"(8621) 5339 9123","substantialshareholders":"Advantech Capital(12.18%),君聯資本(8.53%),HARBOURBIO LLC(7.86%),GIC(6.59%)","principalactivities":"公司是一家臨床階段生物制藥公司，從事研究及開發免疫與腫瘤疾病領域的差異化抗體療法。","website":"http://www.harbourbiomed.com"},"managerinfo":[{"managername":"王勁松","post":"董事會主席、首席執行官兼執行董事","rankno":1},{"managername":"廖邁菁","post":"執行董事","rankno":2},{"managername":"Atul Mukund Deshpande","post":"執行董事","rankno":3}],"investorinfo":[{"institutionname":"BlackRock Funds","shareholding":"18,788,000.0","percentage":13.59,"ReleaseDate":"2021-06-10 00:00:00","relatedparty":"BlackRock, Inc.","subsidiary":["BlackRock Funds"],"InverstorType":"基金"},{"institutionname":"HBM Healthcare Investments (Cayman) Ltd.","shareholding":"6,262,000.0","percentage":4.53,"ReleaseDate":"2021-06-10 00:00:00","relatedparty":"HBM Healthcare Investments AG","subsidiary":["HBM Healthcare Investments (Cayman) Ltd."],"InverstorType":"公司"},{"institutionname":"Hillhouse Funds","shareholding":"6,262,000.0","percentage":4.53,"ReleaseDate":"2021-06-10 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"Hudson Bay Master Fund LTD","shareholding":"6,262,000.0","percentage":4.53,"ReleaseDate":"2021-06-10 00:00:00","relatedparty":"Hudson Bay Capital Management LP","subsidiary":["HBC Asia Healthcare Opportunities V LLC","Hudson Bay Master Fund LTD","HBC Asia Healthcare Opportunities VII LLC"],"InverstorType":"基金"}],"TotalShareholdingPercentage":41.69},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":9}